How long should we continue S-1 as adjuvant chemotherapy for squamous cell carcinoma of the head and neck?

Misato Hirai, Yorihisa Orita, Soshi Takao, Tomoyasu Tachibana, Hidenori Marunaka, Seiichiro Makihara, Kentaro Miki, Yasuyuki Noyama, Sayaka Fuji, Akiko Torigoe, Yasuharu Sato, Kazunori Nishizaki

Research output: Contribution to journalArticle

Abstract

Conclusion: It appears that patients with SCCHN should be recommended to take S-1 for more than 1 year and, if possible, more than 2 years, as adjuvant chemotherapy for SCCHN. Objectives: There is no established consensus on the duration of administration of S-1 as adjuvant chemotherapy for squamous cell carcinoma of the head and neck (SCCHN). Since it might be difficult to undergo prospective randomized study to identify the optimal duration of the administration period of S-1 without a standard, the authors have undergone a retrospective clinical study to decide the tentative standard of therapeutic duration of S-1 as adjuvant chemotherapy for SCCHN. Methods: The clinical records of 89 patients with SCCHN who underwent adjuvant chemotherapy with S-1 were investigated. Results: The median duration of S-1 administration as adjuvant chemotherapy for SCCHN was 7 months (range = 0.1-58 months). Disease-free survivals (DFSs) were generally longer when S-1 administration periods were longer. After adjusting for prognostic factors, S-1 administration periods of 24 months or longer showed significantly lower hazard ratios (HRs) than 0-12 months.

Original languageEnglish
Pages (from-to)1079-1085
Number of pages7
JournalActa Oto-Laryngologica
Volume135
Issue number10
DOIs
Publication statusPublished - Oct 3 2015

Fingerprint

Adjuvant Chemotherapy
S Phase
Disease-Free Survival
Carcinoma, squamous cell of head and neck
Retrospective Studies
Prospective Studies

Keywords

  • adjuvant chemotherapy
  • duration of administration
  • head and neck
  • S-1
  • squamous cell carcinoma

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

How long should we continue S-1 as adjuvant chemotherapy for squamous cell carcinoma of the head and neck? / Hirai, Misato; Orita, Yorihisa; Takao, Soshi; Tachibana, Tomoyasu; Marunaka, Hidenori; Makihara, Seiichiro; Miki, Kentaro; Noyama, Yasuyuki; Fuji, Sayaka; Torigoe, Akiko; Sato, Yasuharu; Nishizaki, Kazunori.

In: Acta Oto-Laryngologica, Vol. 135, No. 10, 03.10.2015, p. 1079-1085.

Research output: Contribution to journalArticle

Hirai, Misato ; Orita, Yorihisa ; Takao, Soshi ; Tachibana, Tomoyasu ; Marunaka, Hidenori ; Makihara, Seiichiro ; Miki, Kentaro ; Noyama, Yasuyuki ; Fuji, Sayaka ; Torigoe, Akiko ; Sato, Yasuharu ; Nishizaki, Kazunori. / How long should we continue S-1 as adjuvant chemotherapy for squamous cell carcinoma of the head and neck?. In: Acta Oto-Laryngologica. 2015 ; Vol. 135, No. 10. pp. 1079-1085.
@article{5116b2b1aa3749f1bf5e640a44e5492c,
title = "How long should we continue S-1 as adjuvant chemotherapy for squamous cell carcinoma of the head and neck?",
abstract = "Conclusion: It appears that patients with SCCHN should be recommended to take S-1 for more than 1 year and, if possible, more than 2 years, as adjuvant chemotherapy for SCCHN. Objectives: There is no established consensus on the duration of administration of S-1 as adjuvant chemotherapy for squamous cell carcinoma of the head and neck (SCCHN). Since it might be difficult to undergo prospective randomized study to identify the optimal duration of the administration period of S-1 without a standard, the authors have undergone a retrospective clinical study to decide the tentative standard of therapeutic duration of S-1 as adjuvant chemotherapy for SCCHN. Methods: The clinical records of 89 patients with SCCHN who underwent adjuvant chemotherapy with S-1 were investigated. Results: The median duration of S-1 administration as adjuvant chemotherapy for SCCHN was 7 months (range = 0.1-58 months). Disease-free survivals (DFSs) were generally longer when S-1 administration periods were longer. After adjusting for prognostic factors, S-1 administration periods of 24 months or longer showed significantly lower hazard ratios (HRs) than 0-12 months.",
keywords = "adjuvant chemotherapy, duration of administration, head and neck, S-1, squamous cell carcinoma",
author = "Misato Hirai and Yorihisa Orita and Soshi Takao and Tomoyasu Tachibana and Hidenori Marunaka and Seiichiro Makihara and Kentaro Miki and Yasuyuki Noyama and Sayaka Fuji and Akiko Torigoe and Yasuharu Sato and Kazunori Nishizaki",
year = "2015",
month = "10",
day = "3",
doi = "10.3109/00016489.2015.1049664",
language = "English",
volume = "135",
pages = "1079--1085",
journal = "Acta Oto-Laryngologica",
issn = "0001-6489",
publisher = "Informa Healthcare",
number = "10",

}

TY - JOUR

T1 - How long should we continue S-1 as adjuvant chemotherapy for squamous cell carcinoma of the head and neck?

AU - Hirai, Misato

AU - Orita, Yorihisa

AU - Takao, Soshi

AU - Tachibana, Tomoyasu

AU - Marunaka, Hidenori

AU - Makihara, Seiichiro

AU - Miki, Kentaro

AU - Noyama, Yasuyuki

AU - Fuji, Sayaka

AU - Torigoe, Akiko

AU - Sato, Yasuharu

AU - Nishizaki, Kazunori

PY - 2015/10/3

Y1 - 2015/10/3

N2 - Conclusion: It appears that patients with SCCHN should be recommended to take S-1 for more than 1 year and, if possible, more than 2 years, as adjuvant chemotherapy for SCCHN. Objectives: There is no established consensus on the duration of administration of S-1 as adjuvant chemotherapy for squamous cell carcinoma of the head and neck (SCCHN). Since it might be difficult to undergo prospective randomized study to identify the optimal duration of the administration period of S-1 without a standard, the authors have undergone a retrospective clinical study to decide the tentative standard of therapeutic duration of S-1 as adjuvant chemotherapy for SCCHN. Methods: The clinical records of 89 patients with SCCHN who underwent adjuvant chemotherapy with S-1 were investigated. Results: The median duration of S-1 administration as adjuvant chemotherapy for SCCHN was 7 months (range = 0.1-58 months). Disease-free survivals (DFSs) were generally longer when S-1 administration periods were longer. After adjusting for prognostic factors, S-1 administration periods of 24 months or longer showed significantly lower hazard ratios (HRs) than 0-12 months.

AB - Conclusion: It appears that patients with SCCHN should be recommended to take S-1 for more than 1 year and, if possible, more than 2 years, as adjuvant chemotherapy for SCCHN. Objectives: There is no established consensus on the duration of administration of S-1 as adjuvant chemotherapy for squamous cell carcinoma of the head and neck (SCCHN). Since it might be difficult to undergo prospective randomized study to identify the optimal duration of the administration period of S-1 without a standard, the authors have undergone a retrospective clinical study to decide the tentative standard of therapeutic duration of S-1 as adjuvant chemotherapy for SCCHN. Methods: The clinical records of 89 patients with SCCHN who underwent adjuvant chemotherapy with S-1 were investigated. Results: The median duration of S-1 administration as adjuvant chemotherapy for SCCHN was 7 months (range = 0.1-58 months). Disease-free survivals (DFSs) were generally longer when S-1 administration periods were longer. After adjusting for prognostic factors, S-1 administration periods of 24 months or longer showed significantly lower hazard ratios (HRs) than 0-12 months.

KW - adjuvant chemotherapy

KW - duration of administration

KW - head and neck

KW - S-1

KW - squamous cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=84938867153&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938867153&partnerID=8YFLogxK

U2 - 10.3109/00016489.2015.1049664

DO - 10.3109/00016489.2015.1049664

M3 - Article

VL - 135

SP - 1079

EP - 1085

JO - Acta Oto-Laryngologica

JF - Acta Oto-Laryngologica

SN - 0001-6489

IS - 10

ER -